Tocagen (TOCA) Coverage Initiated by Analysts at Leerink Swann

Stock analysts at Leerink Swann started coverage on shares of Tocagen (NASDAQ:TOCA) in a research report issued on Monday, The Fly reports. The brokerage set a “market perform” rating and a $10.26 price target on the stock. Leerink Swann’s price target indicates a potential upside of 13.50% from the stock’s previous close.

A number of other research analysts have also issued reports on the company. Robert W. Baird initiated coverage on Tocagen in a research report on Friday, January 18th. They set an “outperform” rating and a $20.00 target price on the stock. B. Riley began coverage on Tocagen in a research note on Monday, December 31st. They issued a “buy” rating and a $22.00 price objective for the company. Finally, Zacks Investment Research raised Tocagen from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Tuesday, January 15th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Tocagen currently has a consensus rating of “Buy” and an average price target of $18.58.

Shares of NASDAQ:TOCA opened at $9.04 on Monday. Tocagen has a 1 year low of $6.47 and a 1 year high of $15.80. The company has a market cap of $228.82 million, a PE ratio of -3.70 and a beta of 3.50. The company has a debt-to-equity ratio of 0.45, a quick ratio of 5.91 and a current ratio of 5.91.

Tocagen (NASDAQ:TOCA) last announced its earnings results on Wednesday, February 27th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.35). Tocagen had a negative net margin of 271.43% and a negative return on equity of 92.56%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. Sell-side analysts expect that Tocagen will post -2.94 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of TOCA. Foresite Capital Management III LLC raised its stake in Tocagen by 347.8% in the 4th quarter. Foresite Capital Management III LLC now owns 665,219 shares of the company’s stock valued at $5,461,000 after purchasing an additional 516,667 shares during the last quarter. Citigroup Inc. raised its stake in Tocagen by 1,917.8% in the 4th quarter. Citigroup Inc. now owns 457,246 shares of the company’s stock valued at $3,754,000 after purchasing an additional 434,585 shares during the last quarter. 683 Capital Management LLC raised its stake in Tocagen by 650.0% in the 4th quarter. 683 Capital Management LLC now owns 375,000 shares of the company’s stock valued at $3,079,000 after purchasing an additional 325,000 shares during the last quarter. BlackRock Inc. raised its stake in Tocagen by 25.2% in the 3rd quarter. BlackRock Inc. now owns 1,413,285 shares of the company’s stock valued at $22,033,000 after purchasing an additional 284,518 shares during the last quarter. Finally, Federated Investors Inc. PA raised its stake in Tocagen by 608,444.7% in the 3rd quarter. Federated Investors Inc. PA now owns 231,247 shares of the company’s stock valued at $3,605,000 after purchasing an additional 231,209 shares during the last quarter. 36.53% of the stock is owned by hedge funds and other institutional investors.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

See Also: FAANG Stocks

The Fly

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit